医疗器械行业月度点评：28省肿标及甲功集采报量结果出炉，国产品牌报量情况较好

Investment Rating - The industry investment rating is "Leading the Market" [3][33] Core Viewpoints - The report highlights that the results of the fifth batch of high-value medical consumables procurement show good performance for domestic brands, with significant market opportunities for companies like Mindray Medical and New Industries [5][32] - The report emphasizes the potential for domestic brands to expand market share and accelerate import substitution due to supply chain advantages and local clinical innovations [33][43] Summary by Sections Market Review - In the past month, the medical device sector experienced a decline of -8.01%, ranking 4th among 6 sub-industries in the pharmaceutical sector [9][13] - The average PE ratio for the medical device sector is 28.62, which is a 9.46% premium over the pharmaceutical sector's average [16][23] Industry Insights - The procurement results for tumor markers and thyroid function tests indicate strong participation from domestic companies, with Mindray Medical and New Industries ranking highly in procurement volume [27][32] - The procurement rules allow for a price drop of over 50% to qualify for selection, providing flexibility and market space for domestic manufacturers [32][33] Key Companies and Dynamics - Key stocks include Mindray Medical (Buy), Weili Medical (Increase), and New Industries (Increase), with projected EPS growth and PE ratios indicating strong future performance [7][36] - Recent developments include Weili Medical's innovative products entering special review procedures and various companies obtaining new product registrations [36][42][47]